The Valley Desk

Clinical trial reportLung cancer (Amsterdam, Netherlands)Published

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Lung cancer (Amsterdam, Netherlands)
Published
Subject terms
Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Acrylamides; Aniline Compounds; Pyrimidines; Indoles; Quinolines; Antineoplastic Combined Chemotherapy Protocols; Treatment Outcome; Mutation; Adult
PubMed ID
41689889
Added to directory
Source checked

Report a correction or request removal